195 related articles for article (PubMed ID: 29132830)
1. Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations.
Manley BJ; Reznik E; Ghanaat M; Kashan M; Becerra MF; Casuscelli J; Tennenbaum D; Redzematovic A; Carlo MI; Sato Y; Arcila M; Voss MH; Feldman DR; Motzer RJ; Russo P; Coleman J; Hsieh JJ; Hakimi AA
Urol Oncol; 2019 Jan; 37(1):12-17. PubMed ID: 29132830
[TBL] [Abstract][Full Text] [Related]
2. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma.
Chakiryan NH; Hajiran A; Kim Y; Aydin AM; Zemp L; Katende E; Nguyen J; Fan W; Cheng CH; Lopez-Blanco N; Chahoud J; Spiess PE; Fournier M; Dhillon J; Wang L; Moran-Segura C; Mulé J; Du D; Yoder SJ; Berglund A; Teer JK; Manley BJ
Eur Urol Focus; 2022 May; 8(3):784-793. PubMed ID: 33994165
[TBL] [Abstract][Full Text] [Related]
3. Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.
Manley BJ; Zabor EC; Casuscelli J; Tennenbaum DM; Redzematovic A; Becerra MF; Benfante N; Sato Y; Morikawa T; Kume H; Fukayama M; Homma Y; Ogawa S; Arcila ME; Voss MH; Feldman DR; Coleman JA; Reuter VE; Motzer RJ; Russo P; Hsieh JJ; Hakimi AA
Eur Urol Focus; 2017 Oct; 3(4-5):421-427. PubMed ID: 28753773
[TBL] [Abstract][Full Text] [Related]
4. Exploration of Morphological Features of Clear Cell Renal Cell Carcinoma With
Liu Y; Li Y; Xu H; Zhou L; Yang X; Wang C
Int J Surg Pathol; 2023 Dec; 31(8):1485-1494. PubMed ID: 36911986
[TBL] [Abstract][Full Text] [Related]
5. Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.
Tennenbaum DM; Manley BJ; Zabor E; Becerra MF; Carlo MI; Casuscelli J; Redzematovic A; Khan N; Arcila ME; Voss MH; Feldman DR; Motzer RJ; Benfante NE; Coleman JA; Russo P; Hsieh JJ; Hakimi AA
Urol Oncol; 2017 Aug; 35(8):532.e7-532.e13. PubMed ID: 28408295
[TBL] [Abstract][Full Text] [Related]
6. Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma - An exploratory analysis.
Mano R; Duzgol C; Ganat M; Goldman DA; Blum KA; Silagy AW; Walasek A; Sanchez A; DiNatale RG; Marcon J; Kashan M; Becerra MF; Benfante NE; Coleman JA; Kattan MW; Russo P; Akin O; Ostrovnaya I; Hakimi AA
Urol Oncol; 2021 Nov; 39(11):791.e17-791.e24. PubMed ID: 34580025
[TBL] [Abstract][Full Text] [Related]
7. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
[TBL] [Abstract][Full Text] [Related]
8. Searching for prognostic biomarkers for small renal masses in the urinary proteome.
Di Meo A; Batruch I; Brown MD; Yang C; Finelli A; Jewett MA; Diamandis EP; Yousef GM
Int J Cancer; 2020 Apr; 146(8):2315-2325. PubMed ID: 31465112
[TBL] [Abstract][Full Text] [Related]
9. Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer Genome Atlas-Renal Cell Carcinoma (TCGA-RCC) Imaging Research Group.
Shinagare AB; Vikram R; Jaffe C; Akin O; Kirby J; Huang E; Freymann J; Sainani NI; Sadow CA; Bathala TK; Rubin DL; Oto A; Heller MT; Surabhi VR; Katabathina V; Silverman SG
Abdom Imaging; 2015 Aug; 40(6):1684-92. PubMed ID: 25753955
[TBL] [Abstract][Full Text] [Related]
10. Prognostic urinary miRNAs for the assessment of small renal masses.
Di Meo A; Brown MD; Finelli A; Jewett MAS; Diamandis EP; Yousef GM
Clin Biochem; 2020 Jan; 75():15-22. PubMed ID: 31672647
[TBL] [Abstract][Full Text] [Related]
11. A Review on the Management of Small Renal Masses: Active Surveillance Versus Surgery.
Marra G; Oderda M; Allasia M; Munegato S; Joniau S; Gontero P
Anticancer Agents Med Chem; 2018; 18(7):940-950. PubMed ID: 29141564
[TBL] [Abstract][Full Text] [Related]
12. Genomic characterization of clear cell renal cell carcinoma using targeted gene sequencing.
Lin PH; Huang CY; Yu KJ; Kan HC; Liu CY; Chuang CK; Lu YC; Chang YH; Shao IH; Pang ST
Oncol Lett; 2021 Feb; 21(2):169. PubMed ID: 33456545
[TBL] [Abstract][Full Text] [Related]
13. Association of Clear Cell Likelihood Score on MRI and Growth Kinetics of Small Solid Renal Masses on Active Surveillance.
Rasmussen RG; Xi Y; Sibley RC; Lee CJ; Cadeddu JA; Pedrosa I
AJR Am J Roentgenol; 2022 Jan; 218(1):101-110. PubMed ID: 34286596
[No Abstract] [Full Text] [Related]
14. Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA.
Kluzek K; Srebniak MI; Majer W; Ida A; Milecki T; Huminska K; van der Helm RM; Silesian A; Wrzesinski TM; Wojciechowicz J; Beverloo BH; Kwias Z; Bluyssen HAR; Wesoly J
Oncotarget; 2017 Apr; 8(17):28558-28574. PubMed ID: 28212566
[TBL] [Abstract][Full Text] [Related]
15. Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis.
Rosellini M; Mollica V; Marchetti A; Coluccelli S; Giunchi F; Tassinari E; Ricci C; Fiorentino M; Tallini G; De Biase D; Massari F
Pathol Res Pract; 2024 Feb; 254():155142. PubMed ID: 38277752
[TBL] [Abstract][Full Text] [Related]
16. The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling.
Sankin A; Hakimi AA; Mikkilineni N; Ostrovnaya I; Silk MT; Liang Y; Mano R; Chevinsky M; Motzer RJ; Solomon SB; Cheng EH; Durack JC; Coleman JA; Russo P; Hsieh JJ
Cancer Med; 2014 Dec; 3(6):1485-92. PubMed ID: 25124064
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of concomitant loss of PBRM1 and BAP1 protein expression in early stages of clear cell renal cell carcinoma.
da Costa WH; da Cunha IW; Fares AF; Bezerra SM; Shultz L; Clavijo DA; da Silva DV; Netto GJ; Guimaraes GC; Cassio Zequi S
Urol Oncol; 2018 May; 36(5):243.e1-243.e8. PubMed ID: 29426696
[TBL] [Abstract][Full Text] [Related]
18. BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.
Eckel-Passow JE; Serie DJ; Cheville JC; Ho TH; Kapur P; Brugarolas J; Thompson RH; Leibovich BC; Kwon ED; Joseph RW; Parker AS
BMC Urol; 2017 Mar; 17(1):19. PubMed ID: 28327121
[TBL] [Abstract][Full Text] [Related]
19. Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma.
Wei X; Choudhury Y; Lim WK; Anema J; Kahnoski RJ; Lane B; Ludlow J; Takahashi M; Kanayama HO; Belldegrun A; Kim HL; Rogers C; Nicol D; Teh BT; Tan MH
Sci Rep; 2017 Aug; 7(1):7342. PubMed ID: 28779136
[TBL] [Abstract][Full Text] [Related]
20. Loss of PBRM1 expression is associated with renal cell carcinoma progression.
Pawłowski R; Mühl SM; Sulser T; Krek W; Moch H; Schraml P
Int J Cancer; 2013 Jan; 132(2):E11-7. PubMed ID: 22949125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]